FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
The lack of an integrated review staff for new drugs and generics has led to "inconsistent" review standards between new drug divisions and the Office of Generic Drugs, the Pharmaceutical Research & Manufacturers of America says in a "white paper" submitted to FDA